COARE Holdings

COARE Biotechnology is a biopharmaceutical company dedicated to developing transformative therapies for cancer and regenerative medicine by targeting cancer stem cells. The company's core technology centers on Doublecortin-like kinase 1 (DCLK1), a specific marker for cancer stem cells that plays a critical role in tumor initiation, maintenance, and metastasis. COARE is advancing a pipeline of monoclonal antibodies and small molecule inhibitors aimed at treating aggressive solid tumors, including pancreatic and colorectal cancers. By selectively targeting the cells responsible for chemoresistance and recurrence, the company seeks to improve long-term outcomes for patients with hard-to-treat malignancies.